greeksoup/ stock research

Bio-Techne (TECH) Q4 FY2026 earnings: revenue $321 million, up 1.3% on the year

Bio-Techne Corp. (TECH) reported revenue of $321 million for Q4 FY2026, the quarter ended 30 June 2026, up 1.3% on the same quarter a year earlier. Net income was $55 million, and diluted earnings per share $0.35. The figures are the company's own, from the 10-K it filed with the SEC on 24 August 2026.

Revenue
$321 million
+1.3% on the year · +3.1% on the quarter
Q1 FY2025Q4 FY2026
Operating margin
23.1%
-7.5% a year earlier
Q1 FY2025Q4 FY2026
Net income
$55 million
+7.0% on the quarter
Q1 FY2025Q4 FY2026
Diluted EPS
$0.35
+9.4% on the quarter
Q1 FY2025Q4 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

  • Fourth-quarter revenue rose 1%: Fourth-quarter net sales were $321.2 million, up 1% reported and 3% organic. A held-for-sale business reduced reported growth by 2 points, and currency had no material effect.
  • Full-year revenue held flat at $1.2 billion: Full-year net sales and organic revenue were both flat at $1.2 billion. Currency added 2 points and the held-for-sale business reduced revenue by 2 points.
  • Adjusted EPS dipped to $0.52: Adjusted diluted EPS was $0.52, against $0.53 a year earlier. Adjusted EPS is a non-GAAP measure reconciled to GAAP in the release.
Read the earnings call summary

Income statement (profit and loss)

$ millionQ4 FY2026Q3 FY2026Q4 FY2025On the quarterOn the yearLast 8 quarters
Revenue321311317+3.1%+1.3%
Cost of revenue110103118+6.5%-7.1%
Gross profit211208199+1.5%+6.3%
Gross margin65.8%66.9%62.7%
Research and development23.923.526.0+2.1%-8.0%
Selling, general and administrative113109197+3.5%-42.4%
Operating income74.375.5-23.9-1.6%
Operating margin23.1%24.2%-7.5%
Interest expense2.12.42.2-11.6%-2.5%
Pre-tax income70.771.2-22.9-0.8%
Income tax16.120.2-5.2-20.4%
Effective tax rate22.7%28.3%n/a
Net income54.651.0-17.7+7.0%
Net margin17.0%16.4%-5.6%
Diluted EPS$0.35$0.32-$0.11+9.4%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ millionQ4 FY2026Q3 FY2026Q4 FY2025On the quarterOn the yearLast 8 quarters
Operating cash flow95.486.798.2+10.1%-2.8%
Capital expenditure8.59.14.9-6.7%+73.4%
Free cash flow86.977.693.3+12.1%-6.8%
Free cash flow margin27.1%24.9%29.4%
Cash from investing-7.1-5.80.4
Cash from financing-33.2-42.7-90.5
Depreciation and amortisation24.124.227.1-0.1%-11.0%
Share-based compensation5.210.54.5-50.2%+14.9%
Buybacks41.70.0n/a
Dividends paid12.512.512.4-0.3%+0.8%
Dividend per sharen/a$0.08n/a
Diluted shares, weighted157m157m156m-0.2%+0.8%
Shares outstanding at period end156m157m155m-0.3%+0.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ4 FY2026Q3 FY2026Q4 FY2025On the quarterOn the yearLast 8 quarters
Shareholders' equity2,1082,0851,919+1.1%+9.9%
Debt2002003460.0%-42.2%
Operating lease liabilities74.276.184.0-2.6%-11.7%
Other liabilities204189209+8.0%-2.3%
Total liabilities and equity2,5872,5512,558+1.4%+1.1%
Fixed assets232233246-0.5%-5.6%
Goodwill975978981-0.3%-0.6%
Intangible assets303319366-4.9%-17.0%
Cash and equivalents265210162+26.2%+63.2%
Receivables217215207+0.9%+4.7%
Inventory196201189-2.7%+3.3%
Other assets399395407+1.0%-2.0%
Total assets2,5872,5512,558+1.4%+1.1%

Questions

What was Bio-Techne's revenue in Q4 FY2026?

Bio-Techne (TECH) reported revenue of $321 million for Q4 FY2026, the quarter ended 30 June 2026, up 1.3% on the same quarter a year earlier.

How much did Bio-Techne earn in Q4 FY2026?

Net income for Q4 FY2026 was $55 million, and diluted earnings per share $0.35.

When did Bio-Techne report Q4 FY2026 results?

Bio-Techne filed its 10-K for the year that ended with the quarter on 24 August 2026; the fourth quarter is the year less the first three.

Quarterly results, the last 20 quarters

Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026 *Q1 FY2027
Revenue269290288270272294301277273303306289297316317287296311321300
Cost of revenue85.688.987.990.188.292.096.691.796.098.810310610310211898.4105103110103
Gross profit184201200180183202205185177205203183194215199188191208211197
Gross margin68%69%70%67%68%69%68%67%65%67%66%63%65%68%63%66%65%67%66%66%
R&D20.621.723.123.922.522.723.424.022.925.824.023.925.024.626.024.223.123.523.926.3
SG&A10189.396.699.493.099.286.8105116112134119121151197116114109113134
Operating income62.390.480.656.367.980.294.555.938.067.045.840.047.438.7-23.947.754.575.574.336.6
Operating margin23%31%28%21%25%27%31%20%14%22%15%14%16%12%-8%17%18%24%23%12%
Interest expense2.92.52.53.82.41.43.74.94.34.02.52.22.12.02.22.92.22.42.12.2
Pre-tax income86.268.879.110466.480.288.349.633.461.141.740.242.938.3-22.948.050.871.270.734.7
Tax rate16%13%22%13%25%12%15%-3%18%20%3%16%19%41%n/a20%25%28%23%18%
Net income80.260.761.589.650.070.275.551.027.549.140.633.634.922.6-17.738.238.051.054.628.3
Net margin30%21%21%33%18%24%25%18%10%16%13%12%12%7%-6%13%13%16%17%9%
Diluted EPS$0.48$0.37$0.38$0.55$0.31$0.43$0.47$0.31$0.17$0.31$0.25$0.21$0.22$0.14-$0.11$0.24$0.24$0.32$0.35$0.18
Operating cash flow10173.110356.164.450.583.459.483.181.075.563.984.341.198.227.682.486.795.473.1
Capital expenditure10.215.113.69.66.111.710.813.614.916.418.09.26.810.14.95.45.99.18.55.9
Free cash flow90.858.089.146.558.338.872.645.868.364.557.554.777.531.093.322.276.577.686.967.2
Buybacksn/a60.8n/a19.60.00.00.0n/an/a0.0n/an/an/a100n/a0.00.00.041.7n/a
Dividends paid12.612.612.512.512.612.612.612.712.612.612.612.712.712.612.412.412.512.512.512.6
Shares outstanding157m157m157m157m157m157m158m158m157m158m158m159m158m157m155m156m156m157m156m157m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 30 June 2026, filed 24 August 2026: the filing.